Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review

 
• By Neena Brizmohun
Calendar Pages
An accelerated assessment can cut months off the EMA's drug review time • Source: Alamy

More from Europe

More from Geography